Biomedical Catalyst – A novel platform for targeted sequence enrichment prior to clinical NGS

牛津基因技术公司将与伯明翰大学的迈克·格里菲斯教授合作，开发新的策略，帮助将下一代测序(NGS)应用到常规临床实践中。NGS在提供改进的早期诊断、知情的治疗选择以及监测疾病进展和缓解方面具有显著优势。就成本和/或性能而言，目前的技术平台对于临床实践并不理想。OGT在基因组技术和服务提供方面拥有丰富的经验。作为一家总部设在英国的生命科学公司，OGT将集中其专业知识来解决目前NGS目标测序技术的一些局限性，并在此过程中，将推动英国在研发和生命科学方面的进一步投资。

Oxford Gene Technology, in collaboration with Professor Mike Griffiths at the University of Birmingham, will develop novel strategies to help implement next generation sequencing (NGS) into routine clinical practice. NGS offers significant benefits in delivery of improved and earlier diagnosis, informed therapeutic selection, and monitoring of disease progression and remission. Current technology platforms are not ideal for clinical practice, in terms of cost and/or performance. OGT has extensive experience in genomic technology and service provision. As a UK based life sciences company, OGT will focus its expertise to address some of the limitations of current NGS targeted sequencing technology, and in the process, will drive further investment in R&D and life sciences in the UK.